Use of real-world evidence for oncology clinical decision making in emerging economies

被引:12
作者
Petracci, Fernando [1 ]
Ghai, Chirag [2 ]
Pangilinan, Andrew [2 ]
Suarez, Luis Alberto [3 ]
Uehara, Roberto [4 ]
Ghosn, Marwan [5 ,6 ]
机构
[1] Inst Alexander Fleming, Breast Canc Dept, Ave Cramer 1180, RA-1426 Buenos Aires, Argentina
[2] Real World Evidence Strategy & Solut, IQVIA, New York, NY 10282 USA
[3] Pfizer Inc, B1607EEV, Buenos Aires, DF, Argentina
[4] Pfizer Inc, New York, NY 10017 USA
[5] France Univ Hosp, Hotel Dieu, Hematol & Oncol Dept, Beirut, Lebanon
[6] St Joseph Univ, Beirut, Lebanon
关键词
Asia-Pacific; effectiveness; electronic database; health policy; Latin America; Middle East; randomized clinical trials; real-world data; real-world evidence; safety; RENAL-CELL CARCINOMA; CANCER-PATIENTS; SUNITINIB; PROGRESSION; RESISTANCE; EFFICACY; THERAPY; TRIALS; SAFETY; HEALTH;
D O I
10.2217/fon-2021-0425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lay abstract Traditionally, randomized clinical trials have been used to provide insights on new medical therapies and continue to remain the gold standard for approval. The-increasing availability of patient level data in the real-world, it is now possible to generate evidence regarding the usage and potential benefits or risks of a medical therapy derived from analysis of real-world data. This evidence is collectively referred to real-world evidence (RWE). randomized clinical trials and RWE are complementary and the area of Oncology especially benefits from RWE to guide clinical decision making across the patient journey. Key benefits include cancer screening and diagnosis, optimal treatment choices (including personalized medicine) and disease management such as dosing and treatment of side effects. In recent times, RWE generation in oncology has been prolific in the USA and western Europe. With expansive biopharmaceutical investments into infrastructure harnessing patient-level data and greater local regulatory guidance, oncology patients in emerging economies may now also have the opportunity to benefit from clinical decision making informed by RWE. Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.
引用
收藏
页码:2951 / 2960
页数:10
相关论文
共 50 条
  • [21] Integration of administrative claims and clinical data to advance real-world evidence generation in oncology
    Nguyen, Chi
    Zheng, Hanke
    Grabner, Michael
    Barron, John
    Dixon, Ruth Wangia
    Cziraky, Mark
    Sweet, Brian
    Hill, Nathan
    CURRENT MEDICAL RESEARCH AND OPINION, 2025,
  • [22] Contributions of Real-World Evidence and Real-World Data to Decision-Making in the Management of Soft Tissue Sarcomas
    Demetri, George D.
    Stacchiotti, Silvia
    ONCOLOGY, 2021, 99 (SUPPL 1) : 3 - 7
  • [23] Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan
    Inamoto, Teruo
    Azuma, Haruhito
    Tatsugami, Katsunori
    Oya, Mototsugu
    Adachi, Masatoshi
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Akaza, Hideyuki
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (07) : 615 - 623
  • [24] Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World
    Burns, Leah
    Le Roux, Nadege
    Kalesnik-Orszulak, Robert
    Christian, Jennifer
    Hukkelhoven, Mathias
    Rockhold, Frank
    O'Donnell, John
    CLINICAL THERAPEUTICS, 2022, 44 (03) : 420 - 437
  • [25] Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
    Menzen, Markus
    Berentzen, Tina Landsvig
    Catarig, Andrei-Mircea
    Pieperhoff, Sebastian
    Simon, Joerg
    Jacob, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) : 205 - 215
  • [26] Real-World Evidence for Equality
    Johnson, C. Erwin
    Whiteside, Yohance Omar
    HEALTH EQUITY, 2021, 5 (01) : 724 - 726
  • [27] Remdesivir Use in the Real-World Setting: An Overview of Available Evidence
    Akinosoglou, Karolina
    Rigopoulos, Emmanouil Angelos
    Schinas, Georgios
    Kaiafa, Georgia
    Polyzou, Eleni
    Tsoupra, Stamatia
    Tzouvelekis, Argyrios
    Gogos, Charalambos
    Savopoulos, Christos
    VIRUSES-BASEL, 2023, 15 (05):
  • [28] Real-world evidence to support health technology assessment and payer decision making: is it now or never?
    Murphy, Linda A.
    Akehurst, Ron
    Cunningham, David
    de Pouvourville, Gerard
    Sola-Morales, Oriol
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2025, 41 (01)
  • [29] Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments
    Kokkotou, Eleni
    Anagnostakis, Maximilian
    Evangelou, Georgios
    Syrigos, Nikolaos K.
    Gkiozos, Ioannis
    CANCERS, 2024, 16 (07)
  • [30] The Expanding Role of Real-World Evidence Trials in Health Care Decision Making
    Klonoff, David C.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (01): : 174 - 179